Upper Limb Spasticity

11 drugs in development·2 companies·4 clinical trials

Drug Pipeline by Phase

Phase 3(3)

Drug	Company
NT 201	Revance Therapeutics, Inc. (RVNC)
recombinant adamts13	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
recombinant botulinum toxin type a	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)

Phase 1(5)

Drug	Company
Sequence 1	Revance Therapeutics, Inc. (RVNC)
Sequence 2	Revance Therapeutics, Inc. (RVNC)
Sequence 3	Revance Therapeutics, Inc. (RVNC)
Sequence 4	Revance Therapeutics, Inc. (RVNC)
Sequence 5	Revance Therapeutics, Inc. (RVNC)

Phase 4(3)

Drug	Company
AboBoNT-A	Revance Therapeutics, Inc. (RVNC)
OnaBoNT-A	Revance Therapeutics, Inc. (RVNC)
Recombinant Botulinum Toxin Type A for injection	Revance Therapeutics, Inc. (RVNC)

BioSniper tracks 11 drugs in development for Upper Limb Spasticity across 2 companies.

There are 4 clinical trials targeting Upper Limb Spasticity tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.